Lundbeck files app for alcohol dependence drug

Lundbeck has filed for European approval of Selincro, a new treatment for alcohol dependence. The Dutch company obtained the treatment in a 96 million euro licensing deal with Biotie. New late-stage data on the drug is due for release in March. "Existing drugs for alcohol dependence require abstinence, which is a very high treatment hurdle," says Biotie CEO Timo Veromaa. "Selincro provides a solution for patients by allowing them to take the drug on an as needed basis, leading to a reduction in their alcohol consumption and number of heavy drinking days." Release | Story

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.